Addex ceo steps down
Replacement being sought for Swiss allosteric modulators developer
André Mueller, chairman of Addex, will act as executive chairman and lead an operational subcommittee of directors to manage the transition until a new ceo is appointed.
Under Mutel's leadership, Addex says it has become a world leader in the field of allosteric modulator drug discovery and has formed significant drug development partnerships with leading pharmaceutical companies.
The board of directors has invited Mutel to consider a possible future advisory role at Addex.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Masters of synthesis
Medicinal chemists take an initial lead compound and through systematic design work improve its potency, efficacy, and properties such as solubility and metabolism. The aim is to create a molecule that is effective, has few side-effects and can be scaled up, initially for clinical trials and subsequently for commercial manufacturing.
Research & Development
Scientists develop new technique to fight antimicrobial resistance
The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development
Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures
A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models